LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s ...

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, ...
Nasdaq

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
Mena FN

Subcutaneous Drug Delivery Devices Market To Reach USD $49.77 Billion By 2030 At 7.5% CAGR

(MENAFN- EIN Presswire) EINPresswire/ -- "Subcutaneous Drug Delivery Devices market to surpass $50 billion in 2030. In comparison, the Drug-Delivery Technology market, which is considered as its ...

New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating ...
Nasdaq

Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD ...

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...

BioArctic: New clinical data on the Leqembi subcutaneous autoinjector presented at AAIC 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference ...